Is Danaher (DHR) Attractive After Recent Share Price Weakness?

Simply Wall St.02-18

If you are wondering whether Danaher at around US$206 per share still offers good value, you are not alone. The answer depends on how you look at its underlying business and valuation. The stock has ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2612413278?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/company-cover/265621-main-header/1756203226349","is_english":true,"pubTime":"2026-02-18 13:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2612413278","market":"sg","top_or_hot":-1,"title":"Is Danaher (DHR) Attractive After Recent Share Price Weakness?","media":"Simply Wall St.","content":"<div>\n<p>If you are wondering whether Danaher at around US$206 per share still offers good value, you are not alone. The answer depends on how you look at its underlying business and valuation. The stock has ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-dhr/danaher/news/is-danaher-dhr-attractive-after-recent-share-price-weakness\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Danaher (DHR) Attractive After Recent Share Price Weakness?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Danaher (DHR) Attractive After Recent Share Price Weakness?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-18 13:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-dhr/danaher/news/is-danaher-dhr-attractive-after-recent-share-price-weakness><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>If you are wondering whether Danaher at around US$206 per share still offers good value, you are not alone. The answer depends on how you look at its underlying business and valuation. The stock has ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-dhr/danaher/news/is-danaher-dhr-attractive-after-recent-share-price-weakness\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1267930730.SGD","symbol_name":"富兰克林美国机遇基金AS Acc SGD (CPF)","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-dhr/danaher/news/is-danaher-dhr-attractive-after-recent-share-price-weakness","article_id":"2612413278","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/company-cover/265621-main-header/1756203226349"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-dhr/danaher/news/is-danaher-dhr-attractive-after-recent-share-price-weakness","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2612413278","pubTimestamp":1771392421,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"If you are wondering whether Danaher at around US$206 per share still offers good value, you are not alone. The answer depends on how you look at its underlying business and valuation.\nThe stock has recently been under pressure, with a 6.1% decline over the last week, a 12.6% decline over the last month and a 10.4% decline year to date, although the 1 year return sits at 1.5%.\nThese moves sit against a backdrop of ongoing interest in large, diversified life sciences and diagnostics...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1267930730.SGD":"富兰克林美国机遇基金AS Acc SGD (CPF)","LU2125909593.SGD":"Natixis Thematics Meta R/A SGD","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0097036916.USD":"贝莱德美国增长A2 USD","LU0511384066.AUD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"A\" (AUDHDG) ACC","LU0107464264.USD":"abrdn SICAV I - GLOBAL INNOVATION EQUITY \"A\" (USD) ACC","IE00BQXX3C00.GBP":"GUINNESS GLOBAL INNOVATORS \"C\" (GBP) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","LU0289960550.SGD":"AB FCP I - GLOBAL EQUITY BLEND PORTFOLIO 'A' (SGD) ACC","LU0289961442.SGD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"AX\" (SGD) ACC","DHR":"丹纳赫","LU2125910179.SGD":"Natixis Thematics Water H-R/A SGD","LU0943347566.SGD":"安联收益及增长平衡基金AM H2-SGD","BK4504":"桥水持仓","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","LU0320765059.SGD":"FTIF - Franklin US Opportunities A Acc SGD","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","LU2063271972.USD":"富兰克林创新领域基金","LU0882574055.USD":"富达全球健康医疗A ACC","LU0390134368.USD":"FRANKLIN GLOBAL GROWTH \"A\" (USD) ACC","BK4588":"碎股","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","LU2211814178.USD":"ALLIANZ CLEAN PLANET \"AT\" (USD) ACC","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","LU2244417387.USD":"FIDELITY SUSTAINABLE US EQUITY \"A\" (USD) ACC","LU2355687059.USD":"NORDEA 1 GLOBAL IMPACT  \"BP\" (USD) ACC","SG9999004303.SGD":"Nikko AM Shenton Global Opportunities SGD","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU1923621640.USD":"Natixis Thematics Water R/A USD","LU0289739343.SGD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"A\" (SGD) ACC","LU2265009873.SGD":"Eastspring Investments - Global Growth Equity AS SGD-H","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","LU1791710582.SGD":"Fidelity Global Demographics A-ACC-SGD (SGD/USD hedged)","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU0528227936.USD":"富达环球人口趋势基金A-ACC","LU0708995401.HKD":"FRANKLIN U.S. OPPORTUNITIES \"A\" (HKD) ACC","LU1917777945.USD":"安联专题基金Cl AT Acc","LU2125909247.SGD":"Natixis Thematics Meta H-R/A SGD","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","BK4581":"高盛持仓","BK4121":"生命科学工具和服务","LU1923622614.USD":"Natixis Thematics Meta R/A USD","LU0109391861.USD":"富兰克林美国机遇基金A Acc","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","DHR.AU":"Dark Horse Resources"},"translate_title":"丹纳赫（DHR）在近期股价疲软后是否有吸引力？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DHR.AU":1.5,"DCF":1,"DHR":1.5},"content_text":"If you are wondering whether Danaher at around US$206 per share still offers good value, you are not alone. The answer depends on how you look at its underlying business and valuation. The stock has recently been under pressure, with a 6.1% decline over the last week, a 12.6% decline over the last month and a 10.4% decline year to date, although the 1 year return sits at 1.5%. These moves sit against a backdrop of ongoing interest in large, diversified life sciences and diagnostics companies, as investors weigh up long term demand for healthcare tools and services. While there is no single headline explaining every price move, this mix of cautious sentiment and steady attention on the sector helps frame how investors are currently thinking about Danaher. On our valuation checks, Danaher scores 2 out of 6, as shown in our valuation summary. We will look at what different methods such as P/E, cash flow and asset based measures suggest about the stock, then finish by highlighting a more complete way to think about valuation that brings these pieces together.  Danaher scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown. AdvertisementApproach 1: Danaher Discounted Cash Flow (DCF) Analysis A Discounted Cash Flow, or DCF, model estimates what a company might be worth today by projecting its future cash flows and then discounting those back to a present value. For Danaher, the model used is a 2 Stage Free Cash Flow to Equity approach, based on cash flow projections and an assumed cost of equity. Danaher’s latest twelve month free cash flow is about $5.1b. Analyst estimates and extrapolations suggest free cash flow could reach around $7.7b by 2029, with ten year projections supplied by a mix of analyst inputs for the earlier years and Simply Wall St extrapolations for the later years. All of these projected cash flows, quoted in $, are discounted back to reflect today’s value. On this basis, the DCF model produces an estimated intrinsic value of about $229.39 per share. Compared with the current share price of roughly $206, the model points to around a 10.0% discount, which suggests the shares are modestly undervalued on this cash flow view. Result: UNDERVALUED Our Discounted Cash Flow (DCF) analysis suggests Danaher is undervalued by 10.0%. Track this in your watchlist or portfolio, or discover 56 more high quality undervalued stocks. DHR Discounted Cash Flow as at Feb 2026 Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Danaher. Approach 2: Danaher Price vs Earnings For profitable companies like Danaher, the P/E ratio is a useful shorthand because it links what you pay for the stock to the earnings the business is currently generating. Higher expected growth and lower perceived risk usually justify a higher P/E, while slower growth or higher risk tend to pull a “normal” or “fair” P/E lower. Danaher currently trades on a P/E of 40.52x. That sits above the Life Sciences industry average of 35.30x and the peer group average of 26.79x, so on simple comparisons the shares look more expensive than many alternatives in the space. Simply Wall St’s Fair Ratio for Danaher is 32.19x. This is a proprietary estimate of what the P/E might be given factors such as the company’s earnings growth profile, profit margins, industry, market cap and risk characteristics. Because it adjusts for these company specific drivers rather than just comparing with broad industry or peer averages, the Fair Ratio can give you a more tailored reference point. Set against this Fair Ratio of 32.19x, Danaher’s actual P/E of 40.52x suggests the shares are trading at a premium on this earnings based view. Result: OVERVALUED NYSE:DHR P/E Ratio as at Feb 2026 P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 23 top founder-led companies. Upgrade Your Decision Making: Choose your Danaher Narrative Earlier we mentioned that there is an even better way to understand valuation. Narratives on Simply Wall St’s Community page let you write the story you believe about Danaher, link that story to specific forecasts for revenue, earnings, margins and a fair value, then constantly update those fair values when fresh news or earnings arrive. This allows you to compare your view of fair value to the current price and decide what to do, whether you lean closer to a more cautious outlook near US$205 per share or a more optimistic view closer to US$310, all within a simple tool used by millions of investors. Do you think there's more to the story for Danaher? Head over to our Community to see what others are saying! NYSE:DHR 1-Year Stock Price Chart  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2612413278","isCrawlerRequest":true}